Welcome to article directory Mesothelioma Blogs . Here You can find interesting and useful information on most popular themes.

There are 202 published articles and 243 registered authors in our article directory.

Recent Articles

Actos Bladder Cancer Lawsuits Notice

By admin | Published January 27, 2012

Actos Bladder Cancer Lawsuits : The incidence of bladder cancer has risen over the past 20 years. Currently, around 54 500 new cases of bladder cancer are diagnosed in the USA each year, and 15 000 cases in the UK. Bladder cancer is the fourth most common cancer in men in the USA and the tenth most common in women. It is one of the most frequent causes of cancer death, accounting for about 10 000 deaths annually in the USA and 5000 in the UK.

More information on Actos Bladder Cancer Lawsuits

The incidence of bladder cancer varies among different patient groups. For example, there is a 3:1 male-to-female ratio, though the prevalence among women appears to be rising.

The incidence is higher in elderly populations, with a median age at presentation of 60-65 years. No evidence exists for a familial or inherited pattern among any patient group, although occasional family clusters have been recorded. In black people the incidence is lower than in white people; in Asian races it appears to be intermediate. The lifetime risk of developing bladder cancer is:

  • 2.8% for white men
  • 0.9% for black men
  • 1.0% for white women
  • 0.6% for black women.

Information from other sources on Actos Bladder Cancer Lawsuits

Five-year survival for both black and white people during the period 1986-92 (60% and 82%, respectively) was significantly better than the equivalent rates for 1974-76 (47% and 74%, respectively; p < 0.05). It is not really known why there are substantial ethnic differences in incidence and prognosis, although putative factors include differences in diet and nutritional status, differences in gene expression (especially of enzymes that may metabolize carcinogens) and differential access to healthcare.

Our use of the term or terms Actos Bladder Cancer Lawsuits is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on (keyword) visit our site often.

Actos Bladder Cancer Lawsuits

Posted in Mesothelioma Blogs | Tagged , |

Yaz Lawsuit News

By admin | Published January 25, 2012

Yaz Lawsuit News 1/23/2012: Until recently, it had appeared self-evident that (nonembolic) arterial thrombosis was the culmination of slow enlargement of the mature atherosclerotic lesion with progressive encroachment into the arterial lumen. This pathobiological construct supported the view that the risk of acute thrombosis was dominated by the sever­ity of arterial stenosis. However, over the past decade, angiographic and patholog­ical data obtained in the coronary arterial bed have challenged this construct. Angiography performed prior to or at the time of acute myocardial infarction has demonstrated that the infarct-related coronary atherosclerotic lesion is frequently not ‘‘critical’’ by standard angiographic criteria. Similarly, pathological examination of culprit lesions has demonstrated that the majority of acute coro­nary events occur with the formation of thrombus at the site of plaques obstruct­ing <50% of the arterial lumen. Taken together with evidence for the impor­tance of plaque disruption in the development of superimposed thrombus (56,65­69), such data have shifted focus from the degree of luminal stenosis to the mor­phological and histological characteristics of the atheromatous plaque that deter­mine its propensity to rupture.

Lending further support to the contribution of inflammatory mechanisms to plaque destabilization, onset of acute thrombosis with or without myocardial necrosis is marked by the production of a number of inflammatory cytokines. In addition, a series of studies have suggested a link between the elabo­ration of inflammatory cytokines and impairment of the ability of smooth muscle cells to maintain the integrity of the fibrous cap (52). Interferon-gamma (IFN-y), a cytokine produced by T-lymphocytes within the atheroma core, decreases the production of collagen by vascular smooth muscle cells (80-82). Smooth muscle cells at the site of plaque rupture or erosion have been found to express high levels of the transplant antigen HLA-DRa, a protein induced only by IFN-y among a wide spectrum of cytokines evaluated

More information on Yaz Lawsuit:

Vascular inflammation may also influence arterial vasomotor function through several possible mechanisms. Increased concentrations of thromboxane A2 and its metabolites produced in acute coronary syndromes (99,100) mediate further platelet aggregation as well as arterial vasoconstriction (101). Leukocytes also produce en- dothelin-1, a potent modulator of vasoconstriction. In addition, certain inflammatory cytokines may increase vascular smooth muscle cell reactivity, as demonstrated in an animal model with IL-1 (102). Finally, inflammatory infiltrates have been documented in the arterial adventitia with vascular nerve involvement and thus have been hypothesized to directly stimulate coronary vasospasm.

In spite of continued advancements in the management of acute ischemic heart disease, morbidity and mortality due to atherosclerotic vascular disease continue to rise globally. Thus, the impetus for improving our strategies for the prevention and management of atherosclerosis has remained strong. In this re­gard, laboratory and experimental research describing key processes in the initia­tion, progression, and destabilization of the atheroma have pointed to novel direc­tions for cardiovascular evaluation and management. In particular, recognition of the role of inflammation in atherothrombosis has directed attention to inflam­matory mediators and indicators as potential targets for risk assessment and for treatment.

Information from other sources on Yaz Lawsuit:

Epidemiological data have established a well-characterized set of vascular risk factors, including advanced age, tobacco use, obesity, diabetes, hypertension, and dyslipidemia. However, up to one-third of first coronary events occur among individuals without these traditional risk factors. Researchers have thus sought to identify inflammatory indicators that might add to these clinical factors for predicting myocardial infarction and stroke. Candidate markers have included several of the cytokines (77,108,109) that promote the recruitment of monocytes in response to endothelial cell dysfunction; intercellular adhesion mol­ecules that mediate the migration of activated monocytes into the subendothelial space; enzymes that might compromise the integrity of the protective fibrous cap, as well as the acute-phase proteins that are produced and released into the systemic circulation in response to inflammatory cytokines.

With systemic levels that are dependent on the rate of de novo hepatic production, CRP levels remain stable over long periods of time in the absence of new stimuli. However, in response to acute tissue injury, infection, or other inflammatory stimuli, CRP levels rise several hundred-fold. As such, CRP and its acute-phase counterpart, serum amyloid A, have been useful in fol­lowing disease activity in chronic inflammatory conditions such as systemic lu­pus, inflammatory bowel disease, and rheumatoid arthritis. Traditional semiquantitative latex agglutination or standard turbidometric methods have been adequate to evaluate such marked elevation of CRP in these disease processes. In contrast, the development of high-sensitivity assays for CRP (hs-CRP) has now enabled detection of CRP within the normal range for healthy individuals. Further, the introduction of high through-put methods with high ana­lytical sensitivity and reproducibility has provided a simple clinical tool to care­fully evaluate the extent of underlying systemic inflammation.

Yaz Lawsuit: More information from other sources related to your search

Antiphospholipid antibodies (APLA) are a heterogeneous group of autoantibod­ies associated with both arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. They can occur either in association with other auto­immune conditions, most frequently systemic lupus erythematosus (SLE), or in isolation, a condition known as the primary antiphospholipid antibody syndrome. In the research laboratory, many antiphospholipid antibodies (with varying epi­tope specificity) can be identified. However, in clinical practice, the antiphospho­lipid antibodies are divided into two large groups, the lupus anticoagulants and the anticardiolipin antibodies.

Lupus anticoagulants or nonspecific inhibitors interfere with the assembly of procoagulant complexes. In vitro, these antibodies are associated with the pro­longation of phospholipid-dependent blood-clotting times. Characteristically, clotting times return to normal with the addition of exogenous phospholipid. Lu­pus anticoagulants may demonstrate specificity for blood-clotting proteins, in particular prothrombin. However, the mechanism by which they promote throm­bosis is unknown. Lupus anticoagulants are likely associated with a high risk of first and recurrent thrombosis as well as recurrent pregnancy loss.

Yaz Lawsuit: Additional News and Information about Yaz Lawsuit:

APLA are found in about 20% of patients presenting with venous thromboembo­lism (1,2), in about 10% of patients presenting with first ischemic stroke (3), and in approximately 5 to 10% of young people presenting with first myocardial infarction (4). Their prevalence in the unselected population is unknown; reported rates vary widely with the test system used and the population being studied. About 30% of individuals with systemic lupus erythematosus have an APLA (5). Low-titer anticardiolipin antibodies are frequently detected in otherwise well individuals; repeat testing reveals a high rate of spontaneous resolution.

All patients with unexplained venous thrombosis, in particular those with thrombosis in unusual sites (such as the cerebral veins or mesenteric veins), should be screened for an antiphospholipid antibody. Both a lupus and an anticar- diolipin antibody should be sought. Testing should be carried out in accordance with the recommendations of the International Society of Thrombosis and He- mostasis, with appropriate confirmatory assays for suspected lupus anticoagu­lants.

Many questions remain unanswered in patients with antiphospholipid antibodies. First, many patients, particularly those with systemic lupus erythematosus, are screened for the presence of an antiphospholipid antibody despite their never having had an episode of thrombosis. When detected, the clinical importance of the antibody is unknown. As a result, some such patients (who are suspected to have a high risk of first thrombosis) are treated with warfarin with varying INR target ranges, while others are treated with aspirin or other antiplatelet agents, and many receive no antithrombotic prophylaxis. To address the need for routine antithrombotic prophylaxis in this problematic patient population, a large, ran­domized clinical trial is currently being carried out. Within this study, adults and children, with both an antiphospholipid antibody and systemic lupus erythemato­sus, are allocated to long-term warfarin with a target INR of 2.0, or no therapy. The primary outcome measure of the study is the rate of objectively confirmed arterial and venous thrombosis.

Our use of the term or terms Yaz Lawsuit: is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Yaz Lawsuit :visit our site often.

http://www.seedol.com

Posted in Mesothelioma Blogs | Tagged , |

Vaginal Lawsuit Petition

By admin | Published January 25, 2012

Vaginal Lawsuit : Oestrogen receptors have been demonstrated in the squamous epithelium of both the proximal and distal urethra.24 Oestrogen has been shown to improve the maturation index of urethral squamous epitheLium.25It has been suggested that oestrogen increases urethral closure pressure and improves pressure transmission to the proximal urethra, both of which promote continence. Epidemiological studies have implicated oestrogen deficiency in the aetiology of lower urinary tract symptoms. Seventy percent of women relate the onset of urinary incontinence to their final menstrual period.2 Lower urinary tract symptoms have been shown to be common in postmenopausal women attending a menopause clinic, with 20% complaining of severe urgency and almost 50% complaining of stress incontinence.

There is, however, conflicting evidence regarding the role of oestrogen withdrawal at the time of the menopause. Some studies have shown a peak incidence in perimenopausal women36‘37 whilst other evidence suggests that many women develop incontinence at least 10 years prior to the cessation of menstruation, with significantly more premenopausal women than postmenopausal women being affected.

For more information on Vaginal Lawsuit follow us on our RSS Feeds.

Urinary tract infection is also a common cause of urinary symptoms in women of all ages. This is a particular problem in the elderly with a reported incidence of 20% in the community and over 50% in institutionalized patients.39‘40 Pathophysiological changes, such as impairment of bladder emptying, poor perineal hygiene and both faecal and urinary incontinence, may partly account for the high prevalence observed. In addition, as previously described, changes in the vaginal flora due to oestrogen depletion lead to colonization with Gramnegative bacilli, which, as well as causing local irritative symptoms, also act as uropathogens. These microbiological changes may be reversed with oestrogen replacement following the menopause, offering a rationale for treatment and prophylaxis.

Information from other sources on Vaginal Lawsuit

Oestrogen preparations have been used for many years in the treatment of urinary incontinence,41‘42 although their precise role remains controversial. Many of the studies performed have been uncontrolled observational series examining the use of a wide range of different preparations, doses and routes of administration. The inconsistent use of progestogens to provide endometrial protection is a further confounding factor making interpretation of the results difficult.

Our use of the term or terms Vaginal Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Vaginal Lawsuit visit our site often.

.

Posted in Mesothelioma Blogs | Tagged , |

Trans Vaginal Mesh Lawsuit Data

By admin | Published January 25, 2012

Trans Vaginal Mesh Lawsuit : Fistulae are rare in England and are usually secondary to gynaecological surgery, maLignancy or radiotherapy. A fistula is an abnormal connection between two epithelial surfaces. Surgical procedures associated with vesicovaginal fistula. Obstetric fistulae are much commoner in the developing world and are a frequent reason why women are cast out of their homes and communities and abandoned. Urethrovaginal and ureterovaginal fistulae are much less common than vesicovaginal fistulae. In the developed world they are unusual causes of urinary incontinence (UI). Once again, the most common cause of these fistuale in the developing world is obstetric trauma due to ischaemic necrosis; in developed countries the most common cause is surgery. Anterior repair, vaginal hysterectomy and urethral diverticulectomy have all been associated with an increased risk of urethral fistula formation.

USI, as opposed to the patient symptom ‘stress urinary incontinence’ (SUI), is only diagnosed after performing urodynamics and is the involuntary leakage of urine per urethram during periods of raised intraabdominal pressure, in the absence of a detrusor contraction. Normal urethral function maintains a positive urethral closure pressure in the presence of raised intraabdominal pressure, although DO may overcome it. An incompetent urethra allows leakage of urine, even in the absence of a detrusor contraction. Damage to the pubo- urethral ligaments and the levator ani muscles (secondary to pregnancy, childbirth, obesity, radical pelvic surgery, abdominopelvic mass or chronic cough, and possibly exacerbated by inherited weak collagen) may allow bladder- neck hypermobility and descent of the bladder neck and proximal urethra, so that they are no Longer within the intraabdominal pressure zone.

For more information on Trans Vaginal Mesh Lawsuit follow us on our RSS Feeds.

demonstrated denervation of the intrinsic and extrinsic sphincter mechanisms.5,6This is known as ‘intrinsic sphincter deficiency’, where the hermetic closure properties of the proximal urethra are lost and USI may be the result. From September 2004 the first drug treatment for SUI, duloxetine, will be available. It is essential to be sure of the diagnosis by excluding DO (see Chapter 6) – a minority of patients opting for a surgical treatment develop irritative symptoms of urgency and frequency or voiding difficulty postoperativeLy, and pre­existing symptoms are likely to be exacerbated.

DO is a urodynamic observation characterized by involuntary detrusor contractions that may be spontaneous or provoked. The contractions occur during the filling phase. Phasic DO is defined by a characteristic waveform that mimics the normal voiding cycle, but which does not inevitably lead to UI. Terminal DO is defined as a single involuntary detrusor contraction at cystometric capacity, which cannot be suppressed, and leads to incontinence – usually complete – and catastrophic bladder emptying.7 Provoked DO is the association of a detrusor contraction with either a physical provocation to the bladder, such as coughing and standing, or a psychological provocation such as hearing running water.

Information from other sources on Trans Vaginal Mesh Lawsuit

Symptomatically, these patients are similar to, and often indistinguishable from, patients with DO. Sometimes, however, low compliance may be associated with a fast bladder-filling rate. Low compliance is seen less often at Patients with DO are often indistinguishable from patients with low compliance; however, low compliance may be associated with a fast bladder-filling rate and is seen less often at physiological filling rates. The incidence of DO increases with age, and urge incontinence is the commonest symptom of incontinence in people aged over 60 years8 and the elderly.9 Urodynamic assessment is required to make an accurate diagnosis, as women usually present with multiple symptoms, most commonly a syndrome of frequency, urgency and nocturia. The pathophysiology of DO is poorly understood and an underlying cause is rarely found, leading to the term idiopathic DO. Detrusor overactivity and USI can coexist as mixed incontinence and DO can arise de novo after incontinence surgery.

Our use of the term or terms Trans Vaginal Mesh Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Trans Vaginal Mesh Lawsuit visit our site often.

Trans Vaginal Mesh Lawsuit

Posted in Mesothelioma Blogs | Tagged , |

Mesothelioma Cancer Information

By admin | Published January 25, 2012

Mesothelioma Cancer : After performing the physical exam and taking a his­tory that concentrates on whether you have developed shortness of breath or pain, the doctor will order a chest x-ray. Based on what is found, the doctor will determine what other tests you will need. The doctor may also order blood work. When a tumor or fluid is found, the doctor will need to perform a procedure that mil obtain cells for the physicians to study to determine whether this is a cancer or not. This can be done by performing a biopsy of the mass or by tapping fluid (inserting a needle and drawing out fluid) from the chest or belly cavity and then analyzing the cells that come with the fluid. The analysis of cells from fluid is called cytology. Although an x-ray or scan may provide useful information about the size, shape, and location of a tumor or fluid and may alert your doctor to the possibility of a cancer, an actual diagnosis of mesothelioma cannot be made without a biopsy, or undeniable evidence of cells in the fluid that have the characteristics of a mesothelioma. Mesothelioma Cancer

For more information on Mesothelioma Cancer follow us on our RSS Feeds.

There are no specific blood tests that can tell your doctor you have mesothelioma. Certain blood cell values may be abnormal when a patient has mesothelioma, but these are nonspecific (that is, they do not definitively tell the doctor that it is mesothelioma or another type of cancer or a benign condition). The white blood cell count (cells that fight infection) may be elevated and/or the platelet count (cells that help the clotting system) maybe elevated above normal values.

The liquid part of blood (serum) is partially comprised of dissolved proteins. Currendy, there are no specific proteins in the serum that can tell your doctor you have asbestosis or mesothelioma. Proteins that are spe­cific to a certain disease are called biomarkers. There is great interest in the discovery of these biomarkers, which may represent unique proteins from the tumor that appear early in the disease and increase as the dis­ease progresses. Ask your physician whether any of these markers are under study or whether any have been approved by the FDA for the study of mesothe­lioma. These markers include soluble mesothelin related protein (SMRP) and osteopontin. Mesothelioma Cancer

Information from other sources on Mesothelioma Cancer

The results of the chest x-ray will usually prompt the doctor to order a CAT or CT scan (computerized axial tomography scan) of the chest and abdomen. These scans provide a three-dimensional view of the area of the body that the physician is interested in. CT scans have a better ability to show how much solid mass is present and how much fluid contributes to the picture. They also give a much better anatomic picture so your doctor can see how any masses relate to the lung, heart, diaphragm (the muscle that helps you breathe), and blood vessels in the chest or abdomen. CT scans do not tell the doctor what type of tumor it is or whether the disease has invaded other structures, but they do give a very good idea of whether your disease can be classified as early with minimal disease (Stage I), later with moderate amount of disease (Stage II), or advanced with a large amount of disease (Stages III and IV). (We will discuss the concept of staging in more detail later on.) In mesothelioma, a CT scan is not very good for showing whether your lymph nodes (the round structures in certain positions in the chest and abdomen that drain the lung and intestines and act as filters and sites for immune responses) are involved. The reason it does not show this well is that the pleura can be thickened in areas where the lymph nodes are, and this lumpy, bumpy thickening can be confused with lymph nodes or can hide lymph nodes.

Our use of the term or terms Mesothelioma Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Mesothelioma Cancer visit our site often.

Mesothelioma Cancer

Posted in Mesothelioma Blogs | Tagged , |

Actos Lawyers Resource

By admin | Published January 25, 2012

Actos Lawyers : Occupational exposure may account for up to 20% of bladder cancers. Those exposed to aniline dyes (used to color fabrics), aldehydes (used in chemical dyes and in the rubber and textile industries) and those using organic chemicals (used in a wide range of occupations) are all at increased risk. Individuals previously treated with radiation to the pelvis or having received cyclophosphamide (a type of chemotherapy) are at markedly increased risk for developing bladder cancer. If your well water is high in arsenic, your risk may also be increased. Studies have also correlated obesity and a high fat diet, especially with increased cholesterol, as a possible contributing factor.

Surprisingly, the answer may be yes. In a recent study, the relationship of diet to cancer was analyzed in a group of47,000 health professionals.[1] In the case of bladder cancer, those who drank the most fluid (greater than 10 cups/day) had half the risk as those who drank the least (less than 5 cups/day). The type of nonalcoholic beverage was less important than the total amount.

For more information on Actos Lawyers follow us on our RSS Feeds.

Although there have been clusters of bladder cancer reported, most researchers believe these may be secondary to risk factors such as smoking and exposure to carcinogens. At this time, there is no convincing evidence bladder cancer risk is hereditary. If an environmental factor caused your cancer and your children are exposed as well, their risk of cancer may be increased. The basic building block of the body is the cell. Cells are specialized to perform a particular function. Skin cells are distinctly different from liver cells which are different from bladder cells. An organ is composed of various cells working in unison to carry out a body function. Cells eventually get old and die. New cells are created by cell division. When cells are behaving normally, they only generate enough new cells to replace the old dying ones. Occasionally, cell growth becomes unchecked. As the cells continue to divide, a tumor (abnormal growth of cells) may form. Such tumors may be benign (no ability to spread beyond their organ of origin) or cancerous (a malignant tumor with the ability to spread beyond their organ of origin and cause harm and possibly death).

Information from other sources on Actos Lawyers

Cell growth is closely regulated by genes which are composed of DNA located in the command center of the cell, the nucleus. When the genes become defective, cell growth can become unregulated, and tumors can develop. Oncogenes, also called cancer genes, can be activated, resulting in uncontrolled cell growth. Other genes which help prevent abnormal cell growth called tumor suppressor genes may be inactivated. Genes can be activated which enhance the tumor cell’s ability to spread throughout the body. The body’s immune system is a critical safeguard against the formation of cancerous tumors, often destroying the abnormal cells before they have a chance to grow and divide.

Cancer cells can spread throughout the body. They can spread through the lymphatic system, composed of lymph channels and lymph nodes, or distantly to other organs or the skeleton via the blood stream (hematogenous spread). In the case of bladder cancer, the cells can also spread by being carried in the urine and implanting in other locations in the urinary tract.

Larger tumors are more likely to spread than smaller tumors. Another critical concern is the grade of the tumor. Normal cells are specialized, differentiated to perform specific function, and have a typical structural arrangement with surrounding cells. As cancers worsen, the cells become less specialized, less differentiated, and lose their normal structural arrangement, resulting in a higher pathologic grade.

Our use of the term or terms Actos Lawyers is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawyers visit our site often.

Actos Lawyers

Posted in Mesothelioma Blogs | Tagged , |

Actos Lawsuit Legal Scoop

By admin | Published January 25, 2012

Actos Lawsuit: To understand cancer, we must first understand nor­mal functioning of the body. The body is made up of billions of cells. Each organ of the body is made up of several different types of specialized cells. For example, the liver has cells that filter toxins from the blood, and the brain has nerve cells (called neurons) that are able to conduct electrical signals. Perhaps the most familiar cells are skin cells. Every flake of dry skin is made of millions of cells that are constantly dying and being replaced with new cells. The growth of new cells is care­fully balanced to occur at the same rate as the death of old cells. Your body has many mechanisms in place to regulate the timing of the birth and death of cells. Unfortunately, if one of these mechanisms malfunc­tions, the careful balance can be disrupted. Environ­mental toxins such as cigarette smoke, chemicals, and radiation can damage DNA and can disrupt these control mechanisms. A tumor may develop when new cells are created faster than old cells die. Tumors can be either benign or malignant. A benign tumor is an overgrowth of cells that is unchecked by the body’s normal mechanisms; thus, it will keep getting bigger. It is called benign because it does not cause you illness. Some benign tumors can get to be so large that they do cause problems, especially if they are in a confined space, such as your skull. A malignant tumor is also an overgrowth of cells.

You can live without a bladder. However, you still need something that can perform the two basic func­tions of the bladder: storing and emptying of urine. Physicians have come up with many ways over the years to accomplish these tasks, many of which are still used today. The simplest alternative is to place drainage tubes into the kidneys that come out through the skin and connect to bags on the abdomen. These tubes are known as nephrostomy tubes. Nephrostomy tubes are typically inserted into a person in the X-ray department by an interventional radiologist who uses some light sedation. For the patient, the bag provides an easy way to store urine and can be drained several times a day when convenient by opening a small valve on the bag.

For more information on Actos Lawsuit follow us on our RSS Feeds.

To provide a good long-term solution, surgeons most commonly use a portion of the small bowel to act as the new bladder. The identified piece of small bowel is removed from the main portion and is fashioned for its new use (see Question 79 for details). The urine that collects within this piece of bowel will ultimately be drained in one of three ways. First, the bowel can simply be left open at the skin for the urine to drain passively out into a bag that is attached to the abdomen. This type of drainage is known as a conduit, and the opening onto the skin is called a urostomy. Urine collects in the bag, which is then drained into a toilet several times each day. Second, the bowel can be sewn into a rough sphere con­nected to the skin by only a small, long channel. This channel prevents urine from leaking out but easily accommodates a small catheter. This is called a conti­nent urinary diversion. With this type of diversion, you must pass a catheter into the new bladder several times a day to drain the urine. This allows you to live without an ostomy bag, but for some patients, passing the catheter several times a day may be difficult or impossible. Third, the new bladder can be directly reattached to the urethra (called an orthotopic neobladder).

Information from other sources on Actos Lawsuit

Bladder cancer is a malignant overgrowth of the cells of the bladder. Most commonly, the growth occurs in cells that are in the urothelium. The lining of most hollow spaces in the body is made of epithelial cells. The lining of the inside of your cheek, for instance, is an epithelial cell lining. Also, the lining of your stomach, bowels, gallbladder, and—you guessed it—the bladder is made of epithelial cells. Each organ has its own subset of epithelial cells. In the bladder, the lining cells are called transitional epithelial cells. The cancer that grows from these cells is then called transitional cell cancer; 90% to 95% of all bladder cancers are of this type. If the cancer grows from a different type of cell in the bladder, it is given a different name. Other types of uncommon cancers in the bladder include squamous cell carcinoma and adenocarcinoma.

It is also possible that cancer in the bladder did not begin there but spread to the bladder from somewhere else. The bladder is an uncommon place for other tumors to “seed” (or metastasize), but it does occasionally occur. Although metastases are uncommon, tumors can occa­sionally grow directly into the bladder from an adjacent organ, such as the prostate, colon, rectum, or cervix. Bladder cancer is the fourth most common type of cancer in men and the eighth most common in women. The American Cancer Society estimated that in 2009, there would be about 70,980 new cases of bladder cancer diagnosed in the United States. In 2009, 14,330 deaths were expected from bladder cancer. In spite of the increased incidence of bladder cancer over the years, the rate of people dying from bladder cancer has decreased over the past 20 years.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

Actos Lawsuit

Posted in Mesothelioma Blogs | Tagged , |

Actos Cancer Updates

By admin | Published January 25, 2012

Actos Cancer : Radiation therapy for bladder cancer is commonly deliv­ered with a machine that focuses an invisible external beam on die area that requires treatment. The procedure is painless and similar to having an ordinary X-ray done. In the usual approach, your doctors will use your CT scan as a road map of your abdomen and pelvis to pinpoint your tumor and aim the beam at it. In another type of radiotherapy, doc­tors implant a small pellet or needle of radioactive material directly into your cancer. (This is rarely used for bladder cancer these days.)

For more information on Actos Cancer follow us on our RSS Feeds.

When radiation is used alone or with chemotherapy, there is an increased likelihood that your other organs, such as the prostate and uterus, will remain functional, as does your ability to void urine normally and have sex. The intention when chemotherapy ^¿radiotherapy are given is usually to improve the chances of curing the cancer while preserving the bladder and avoiding the need to remove it surgically. This area is still somewhat controversial; some physicians believe that this approach is nearly as effective as surgical removal of the bladder, but others feel that cystec­tomy is the best treatment. The decision of which treatment to pursue depends in part upon the physical fitness of the patient as well as upon the patients personal preferences.

Radiotherapy is not without side effects. Radiation can scar bladder tissue, and the scarring can reduce the amount of urine your bladder can hold as the bladder wall becomes less distensible. As a result you may experience an increase in the number of times you have to urinate, which can be irritating, especially at night. You also may experience an increase in bouts of cystitis.

There has been much discussion in the medical commu­nity about whether the results achieved by radiotherapy are the same as those from cystectomy with respect to achieving cure. We think that when one considers all types of blad­der cancer, in the hands of a highly experienced urologist who specializes in this operation, cystectomy gives better results than radiotherapy. However, there are some patients, particularly those with other significant medical conditions, who will benefit from radiotherapy, despite the possibility of a lower chance of permanent cure. In some centers, such as Massachusetts General Hospital, where the techniques of chemo radio therapy and bladder preservation have been piloted, a urologist will perform a cystoscopy about halfway through the planned course of radiotherapy. If the tumor is shrinking well, radiotherapy will be completed. However, if it appears that the cancer is not responding to radiother­apy, the plan will be abandoned and replaced with a radical cystectomy.

Information from other sources on Actos Cancer

There are no absolute guidelines for follow-up after cystec­tomy. What is right for you will depend on your situation: the type of urinary diversion system you have, whether you received chemotherapy and/or radiotherapy, and what, if any, side effects you are dealing with. A reasonable guide for follow-up, however, is to expect a physical exam, chest X-ray, urine test, and blood work every three months for the first year, every four months for the next two years, and then twice a year for life. We usually recom­mend an annual CT or MRI for the first five years at least.

As with superficial cancer, if you have any of the symp­toms discussed in chapter 1, check in with your doctor. Call your doctor if you have blood in your urine or an increase in the urge or frequency of urination. It might be an infec­tion, but the best thing to do is to make contact without unnecessary delay.

Our use of the term or terms Actos Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Cancer visit our site often.

Actos Cancer

Posted in Mesothelioma Blogs | Tagged , |

Actos Attorneys Resource

By admin | Published January 25, 2012

Actos Attorneys: When an individual has diffuse, high grade cancer of the bladder, even when superficial, bladder removal may be warranted. Many may have widespread carcinoma in situ (CIS) in conjunction with papillary disease. One can expect a high rate of recurrence and a high rate of progression to invasive disease. Generally, intravesical therapy is tried first. If this therapy is unsuccessful, repeated therapy or alternate intravesical therapies can be tried. However, with failure of intravesical therapy, further trials may prove to be equally ineffective and lead to unnecessary delay for potentially definitive curative therapy. Many recommend removal of the bladder if two courses of six weeks of BCG are ineffective. Therefore, radical cystectomy is a treatment option for any individual who is thought to be at significant risk for progression to musclc invasive and potentially metastatic disease.

For individuals with recurrent disease despite tumor removal and intravesical therapy, progression to a more serious, muscle invasive disease is common. The patient at high risk for progression must consider radical cystectomy. If the individual is not a candidate for radical cystectomy because of poor health or the individual refuses cystectomy, radiation therapy can be considered. There are no good studies available and it is difficult to assess the efficacy of radiation alone since it is always combined with TURBT and the completeness of tumor resection is an uncertain variable. In general, radiation plays a minimal role in the treatment of superficial bladder cancer.

For more information on Actos Attorneys follow us on our RSS Feeds.

For those individuals whose bladder tumors are at high risk for recurrence or progression, instillation of agents directly into the bladder can be worthwhile. The forms of therapeutic agents come in two groups: chemotherapy or immunotherapy. It is fortunate the bladder is readily accessible to these agents, allowing for direct action with minimal systemic side effects.

Those individuals at high risk for recurrence and or progression should be considered for this therapy. Individuals with multiple or diffuse superficial tumors, large tumors, high grade tumors, superficially invasive tumors, those with recurrence within one year, or individuals with CIS all should be considered for this treatment. In addition, those with positive cytology after resection or patients with persistent superficial tumors which could not be removed should also be considered.

Information from other sources on Actos Attorneys

The agent is passed via a catheter into the bladder. The passage of the catheter generally takes just a few seconds in a woman, and perhaps ten seconds in a man. The urethral meatus (the outermost part of the urethra) is first cleansed with an antiseptic solution and then the catheter, which is made slippery with a sterile lubricant, is inserted up the urethra and into the bladder. On passage of the catheter, there is minor, short lived discomfort which may be reduced by an injection up the urethra with numbing medication. The various therapeutic agents are not painful during the infusion but may cause side effects afterwards. Depending on the agent instilled, the patient is asked not to void for a period of time afterwards to allow the agent to have its maximal effect on the bladder lining.

BCG is a living but attenuated form of tuberculosis bacteria. Similar to other living vaccines, it is used to create a heightened immunity. There are a number of precautions which must be taken to make sure the BCG is infused safely. BCG should not be infused immediately or shortly after tumor resection. Several weeks should be allowed to pass so the BCG does not gain access into open blood vessels. In addition, BCG should not be infused if the individual has a urinary infection, has active bleeding, or if the catheterization is traumatic and causes bleeding. It should not be used in patients whose immune system is seriously compromised or for those on steroids, which can decrease the immune system.

Our use of the term or terms Actos Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Attorneys visit our site often.

Actos Attorneys

Posted in Mesothelioma Blogs | Tagged , |

Actos Lawsuit Action

By admin | Published January 25, 2012

Actos Lawsuits : The stage is very important in determining the treatment that you will receive. There is a good barrier between the urothelium and the muscle of the bladder wall. If the tumor is kept within this barrier, the tumor can usually be completely removed with a transurethral resection of bladder tumor (TURBT) (Question 38). If the tumor has become more aggressive, it may figure out how to pass through this barrier. When the tumor has gotten through the protective layer, it becomes much more likely to spread outside of the bladder to other organs or lymph nodes. Once the tumor has gotten through the urothelium, simple scraping of the tumor is not likely to get all of the tumor out, and further therapy will be necessary—either surgery, chemotherapy, or radiation. The option that you and your doctor choose will depend on the extent of spread of the tumor and your overall health status.

Over the years, several different systems have been used to stage cancers. In an effort to ease confusion between different systems, doctors around the world met and decided to create a new staging system that would be relevant for all different types of cancer. This system is called TNM. The letters stand for Tumor size, lymph Node status, and the extent of Metastases.

For more information on Actos Lawsuits follow us on our RSS Feeds.

“Upper tract studies” are evaluations that your doctor does of your kidneys and ureters. The lining of the bladder is the urothelium. The same urothelium also lines the ureters and the inside of the kidneys. The kidneys and the ureters are then also potential locations of transitional cell cancer. The study that your doctor chooses depends on his or her personal opinion as well as the availability of each test at your hospital. Even if the upper tract study is negative, you will likely need to repeat the studies periodically. Patients with low-grade tumors have a low risk (approximately 2%) of developing upper tract tumors. The presence of a high-grade tumor or of diffuse carcinoma in situ, however, carries up to a 40% lifetime risk of developing an upper tract tumor.

Information from other sources on Actos Lawsuits

An ultrasound is often the easiest test to obtain and is therefore popular as a first study. Ultrasound technology generates sound waves and then measures their reflections off of internal structures to produce an image. The same imaging is used for obstetric ultrasounds to produce an image of the fetus. There is no radiation with an ultrasound. An ultrasound is very good for showing tumors and stones in the kidneys and for showing obstruction of the ureter causing hydronephrosis. It is not as good for showing small tumors inside the ureter or renal pelvis, and thus a second kind of study is usually needed in addition to the ultrasound.

Our use of the term or terms Actos Lawsuits is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuits visit our site often.

Actos Lawsuit

Posted in Mesothelioma Blogs | Tagged , |